These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35562487)

  • 1. Natural LILRB1 D1-D2 variants show frequency differences in populations and bind to HLA class I with various avidities.
    Liu F; Cocker ATH; Pugh JL; Djaoud Z; Parham P; Guethlein LA
    Immunogenetics; 2022 Dec; 74(6):513-525. PubMed ID: 35562487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic diversity of the LILRB1 and LILRB2 coding regions in an admixed Brazilian population sample.
    Oliveira MLG; Castelli EC; Veiga-Castelli LC; Pereira ALE; Marcorin L; Carratto TMT; Souza AS; Andrade HS; Simões AL; Donadi EA; Courtin D; Sabbagh A; Giuliatti S; Mendes-Junior CT
    HLA; 2022 Oct; 100(4):325-348. PubMed ID: 35754199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of the LILRB1 inhibitory receptor with HLA class Ia dimers.
    Baía D; Pou J; Jones D; Mandelboim O; Trowsdale J; Muntasell A; López-Botet M
    Eur J Immunol; 2016 Jul; 46(7):1681-90. PubMed ID: 27109306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for Epistatic Interaction between
    Oliveira-Caramez ML; Veiga-Castelli L; Souza AS; Cardili RN; Courtin D; Flória-Santos M; Donadi E; Giuliatti S; Sabbagh A; Castelli EC; Mendes-Junior CT
    Cells; 2023 Feb; 12(4):. PubMed ID: 36831297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LILRB1 polymorphisms influence posttransplant HCMV susceptibility and ligand interactions.
    Yu K; Davidson CL; Wójtowicz A; Lisboa L; Wang T; Airo AM; Villard J; Buratto J; Sandalova T; Achour A; Humar A; Boggian K; Cusini A; van Delden C; Egli A; Manuel O; Mueller N; Bochud PY; ; Burshtyn DN
    J Clin Invest; 2018 Apr; 128(4):1523-1537. PubMed ID: 29528338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structures of the four Ig-like domain LILRB2 and the four-domain LILRB1 and HLA-G1 complex.
    Wang Q; Song H; Cheng H; Qi J; Nam G; Tan S; Wang J; Fang M; Shi Y; Tian Z; Cao X; An Z; Yan J; Gao GF
    Cell Mol Immunol; 2020 Sep; 17(9):966-975. PubMed ID: 31273318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of cytomegalovirus infection and leukocyte immunoglobulin like receptor B1 polymorphisms on receptor expression in peripheral blood mononuclear cells.
    Cadena-Mota S; Monsiváis-Urenda A; Salgado-Bustamante M; Monjarás-Ávila C; Bernal-Silva S; Aranda-Romo S; Noyola DE
    Microbiol Immunol; 2018 Dec; 62(12):755-762. PubMed ID: 30461037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of HLA-G, LILRB1 and LILRB2 gene polymorphisms on susceptibility to and severity of endometriosis.
    Bylińska A; Wilczyńska K; Malejczyk J; Milewski Ł; Wagner M; Jasek M; Niepiekło-Miniewska W; Wiśniewski A; Płoski R; Barcz E; Roszkowski P; Kamiński P; Malinowski A; Wilczyński JR; Radwan P; Radwan M; Kuśnierczyk P; Nowak I
    Mol Genet Genomics; 2018 Jun; 293(3):601-613. PubMed ID: 29234882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extensive polymorphisms of LILRB1 (ILT2, LIR1) and their association with HLA-DRB1 shared epitope negative rheumatoid arthritis.
    Kuroki K; Tsuchiya N; Shiroishi M; Rasubala L; Yamashita Y; Matsuta K; Fukazawa T; Kusaoi M; Murakami Y; Takiguchi M; Juji T; Hashimoto H; Kohda D; Maenaka K; Tokunaga K
    Hum Mol Genet; 2005 Aug; 14(16):2469-80. PubMed ID: 16014635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of LILRB1 but not LILRA3 gene polymorphism in immunopathology of ankylosing spondylitis-A parallel to KIR genes.
    Majorczyk E; Wiśniewski A; Zoń-Giebel A; Chlebicki A; Wiland P; Kuśnierczyk P
    Int J Immunogenet; 2019 Jun; 46(3):146-151. PubMed ID: 30892832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of the immunoregulatory receptor LILRB1 as a crystallisation chaperone for human class I MHC complexes.
    Mohammed F; Stones DH; Willcox BE
    J Immunol Methods; 2019 Jan; 464():47-56. PubMed ID: 30365927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic polymorphisms and expression of HLA-G and its receptors, KIR2DL4 and LILRB1, in non-small cell lung cancer.
    Wiśniewski A; Kowal A; Wyrodek E; Nowak I; Majorczyk E; Wagner M; Pawlak-Adamska E; Jankowska R; Ślesak B; Frydecka I; Kuśnierczyk P
    Tissue Antigens; 2015 Jun; 85(6):466-75. PubMed ID: 25855135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leukocyte immunoglobulin-like receptor B1 and B4 (LILRB1 and LILRB4): Highly sensitive and specific markers of acute myeloid leukemia with monocytic differentiation.
    Churchill HRO; Fuda FS; Xu J; Deng M; Zhang CC; An Z; Zhang N; Chen P; Bergstrom C; Kansagra A; Collins R; John S; Koduru P; Chen W
    Cytometry B Clin Cytom; 2021 Jul; 100(4):476-487. PubMed ID: 32918786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LILRB1-HLA-G axis defines a checkpoint driving natural killer cell exhaustion in tuberculosis.
    Wang J; Chai Q; Lei Z; Wang Y; He J; Ge P; Lu Z; Qiang L; Zhao D; Yu S; Qiu C; Zhong Y; Li BX; Zhang L; Pang Y; Gao GF; Liu CH
    EMBO Mol Med; 2024 Aug; 16(8):1755-1790. PubMed ID: 39030302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LILRB1 polymorphism and surface phenotypes of natural killer cells.
    Davidson CL; Li NL; Burshtyn DN
    Hum Immunol; 2010 Oct; 71(10):942-9. PubMed ID: 20600445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer.
    Zeller T; Münnich IA; Windisch R; Hilger P; Schewe DM; Humpe A; Kellner C
    Front Immunol; 2023; 14():1240275. PubMed ID: 37781391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible Role of HLA-G, LILRB1 and KIR2DL4 Gene Polymorphisms in Spontaneous Miscarriage.
    Nowak I; Malinowski A; Barcz E; Wilczyński JR; Wagner M; Majorczyk E; Motak-Pochrzęst H; Banasik M; Kuśnierczyk P
    Arch Immunol Ther Exp (Warsz); 2016 Dec; 64(6):505-514. PubMed ID: 26973020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LILRA3 binds both classical and non-classical HLA class I molecules but with reduced affinities compared to LILRB1/LILRB2: structural evidence.
    Ryu M; Chen Y; Qi J; Liu J; Fan Z; Nam G; Shi Y; Cheng H; Gao GF
    PLoS One; 2011 Apr; 6(4):e19245. PubMed ID: 21559424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KIR3DL1 polymorphisms that affect NK cell inhibition by HLA-Bw4 ligand.
    Carr WH; Pando MJ; Parham P
    J Immunol; 2005 Oct; 175(8):5222-9. PubMed ID: 16210627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative mRNA splicing creates transcripts encoding soluble proteins from most LILR genes.
    Jones DC; Roghanian A; Brown DP; Chang C; Allen RL; Trowsdale J; Young NT
    Eur J Immunol; 2009 Nov; 39(11):3195-206. PubMed ID: 19658091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.